Literature DB >> 8410067

Treatment of spasticity in children with low dose benzodiazepine.

M Dahlin1, E Knutsson, A Nergårdh.   

Abstract

In an attempt to investigate whether benzodiazepines at low dosage have a significant effect in reducing spasticity among children with cerebral palsy, we carried out a double-blind, placebo-controlled, cross-over study. Twelve children with either spastic diplegia or hemiplegia participated in this study. The mean age was 14 years. The restraint of passive knee movements was determined with a dynamic dynamometer and spastic stretch reflexes were measured as EMG activity in muscles stretched. Clonazepam was given at low dosage (0.02 mg/kg body weight). In each child measurements of passive restraint were made on 2 different days immediately before and 3 h after an i.m. injection of either clonazepam or placebo in randomized order. Clonazepam significantly reduced spastic restraint (P < 0.001) compared to non-significant reduction with placebo. The mean plasma concentration of clonazepam at time of spasticity evaluation was 21 mmol/l which is in the low dose range, far below conventional doses. The study thus shows a positive effect of low dose clonazepam in reducing spasticity in children when given as a single dose.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410067     DOI: 10.1016/0022-510x(93)90154-q

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

Review 1.  Treatment of Disorders of Tone and Other Considerations in Pediatric Movement Disorders.

Authors:  Stephen R Deputy; Ann H Tilton
Journal:  Neurotherapeutics       Date:  2021-01-06       Impact factor: 7.620

Review 2.  Therapeutic interventions for tone abnormalities in cerebral palsy.

Authors:  Ann H Tilton
Journal:  NeuroRx       Date:  2006-04

3.  Prescription Benzodiazepine Use in Privately Insured U.S. Children and Adolescents.

Authors:  Greta A Bushnell; Stephen Crystal; Mark Olfson
Journal:  Am J Prev Med       Date:  2019-12       Impact factor: 5.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.